Warning Letter — vapenovaco.com
The FDA Center for Tobacco Products issued a warning letter to vapenovaco.com following an assessment of their online retail activities. The source indicates regulatory violations related to the sale of tobacco products.
This notice affects the owners and operators of vapenovaco.com, as well as regulatory and compliance departments within the electronic nicotine delivery systems (ENDS) and e-commerce retail sectors.
The issuance of this warning letter suggests continued FDA scrutiny of online tobacco retailers and e-liquid distributors. For industry professionals, this reinforces the necessity of ensuring that all tobacco products sold in the U.S. have received appropriate premarket authorization. Failure to address such notices typically leads to further oversight, potential civil money penalties, or product seizures.
E-commerce stakeholders should immediately review product listings for required marketing authorizations. Compliance teams must verify that all tobacco products offered for sale are the subject of an FDA marketing order and that all online distribution platforms adhere strictly to CTP regulations.
FDA Warning Letter issued to: vapenovaco.com. 05/19/2026 — Center for Tobacco Products. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/vapenovacocom-730110-05192026
Open in openFDA / FDA.gov